The Only Good Antibodies (OGA) community was established to address the antibody reliability crisis that affects scientific research and drug development.
We collaborate with researchers, industry leaders, publishers, funders, and patient advocacy groups.
Only Good Antibodies Community
Loading...
Meet Abigail Parsons, one of our Antibody Champions. Abi joins a UK wide network helping their institutions make better antibody choices through local workshops and free tools built by OGA
onlygoodantibodies.co.uk/champions/
#BrainCancer #3Rs #AntibodyValidation #ReproducibleResearch #OpenScience
Only Good Antibodies Community
Say hello to our Antibody Champions, supporting institutions across the UK! Better Antibodies, Better Science, Better Patient Outcomes!
Better antibodies, Better science, Better patient outcomes. Visit us to find out more!
onlygoodantibodies.com/projects/
Congratulations Michael Biddle for your nomination for this award recognising contributions to #Open , #Reproducible , and generally better research!
www.ukrn.org/2025/03/04/d...
Congratulations Michael Biddle for winning the @ukrepro.bsky.social Dorothy Bishop award for your contributions to #Open and #Reproducible research culture. We are so proud of all of the excellent work you have been leading!
Learn more about us and our collaboration with @ycharos.bsky.social in this @nature.com feature by Diana Kwon.
www.nature.com/articles/d41...
Poorly performing antibodies have plagued biomedical sciences for decades. Several fresh initiatives hope to change this.
www.nature.com
Only Good Antibodies Community
Only Good Antibodies Community
Only Good Antibodies Community
⚠️ Half of commercial antibodies miss their target!
So how do you pick the right one for your experiment?
Here’s the solution 👉
Antibody characterization data (all tested in KO cells) are now available at:
🔗 onlygoodantibodies.co.uk
Tested by @ycharos.bsky.social & @oga-community.bsky.social
Abcam/YCharOS UK/Only Good Antibodies Business Dev, Lunch and learn more about open antibody quality control data to inform more robust biomarker and drug target validation/discovery.
Limited spaces. Email [email protected] 5th march. 1-2pm. GDC 0.25-0.27 @oga-community.bsky.social
